Coherus Oncology, Inc. (CHRS) vs Compass Therapeutics, Inc. (CMPX)
A side-by-side comparison of Coherus Oncology, Inc. and Compass Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CHRS
Coherus Oncology, Inc.
$1.04HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT
CMPX
Compass Therapeutics, Inc.
$0.97HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT
Total return — CHRS vs CMPX
growth of $100 · dividends reinvested · last 6yCHRS -92.3% (-34.7%/yr)CMPX -88.7% (-30.5%/yr)CMPX compounded faster over this window
CHRS CMPX
CHRS vs CMPX: by the numbers
- •CMPX is the larger company ($175M vs $160M market cap).
- •Both run net losses; CMPX's is the smaller (0.00% vs -257.10% net margin).
Metrics side by side
Valuation
| Metric | CHRS | CMPX |
|---|---|---|
| P/S ratio | 3.14 | N/A |
| P/B ratio | 2.63 | 1.06 |
Profitability
| Metric | CHRS | CMPX |
|---|---|---|
| Gross margin | 63.55% | 0.00% |
| Operating margin | -425.72% | 0.00% |
| Net margin | -257.10% | 0.00% |
| ROE | -215.26% | -44.23% |
| ROIC | -135.38% | -46.59% |
Growth (annualized)
| Metric | CHRS | CMPX |
|---|---|---|
| Revenue CAGR (5Y) | -33.60% | N/A |
| Total return CAGR (5Y) | -41.38% | -22.79% |
Frequently asked
- How have CHRS and CMPX total returns compared?
- Over the past 5 years, CHRS delivered -41.38% and CMPX delivered -22.79% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.